netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Statins May Treat Dry AMD

Left: before statin treatment; right: same patient, one year after statin treatment. Photo: Harvard University

 RPB-supported researchers at Massachusetts Eye and Ear/Harvard Medical School and scientists at University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins (cholesterol-lowering medications) for the treatment of patients with the dry form of age-related macular degeneration (AMD) — the leading cause of blindness in the developed world. Although effective treatments are available for the wet form of AMD, they are currently lacking for the more prevalent dry form.

The researchers found evidence that treatment with high-dose atorvastatin (80mg) is associated with regression of lipid deposits and improvement in visual acuity, without progression to advanced disease, in high-risk AMD patients.

Read the story.

Read the study.

Related News: Feature Story, Macular Degeneration, Top Story

eye brain connection

RPB Grantees Contribute to Eye Transplantation Effort

The ARPA-H THEA project takes on an exciting challenge.

Read More

 
microscope

Faulty Vision for US Eye Research

An important message from an RPB Trustee

Read More

 
Giving Tuesday logo

Giving the Gift of Sight

#GivingTuesday kicks off with a donation match

Read More

 
eye photo

New Grants for Big Data Research to Improve Vision Care

Read More

 
RPB Logo

Research to Prevent Blindness Opens Applications for Vision Research Grants

The awards offered cover a wide variety of topics in vision science, including glaucoma, age-related macular degeneration, retinal diseases, and many more.

Read More

 
RPB logo

Vision Research Funding Partnership Event Takes Place Today

Leaders of organizations that fund vision research convene in Washington, D.C. to increase collaboration and maximize the impact of research funding for sight-threatening diseases.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.